Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Pharmaceutical Outfits, While Closing Discovery Centers In Japan, Are Forging Alliances With Japanese Researchers (Part 3 Of 3)

This article was originally published in PharmAsia News

Executive Summary

Several multinational pharmaceutical companies have shut down their Japan-based discovery research facilities over the last few years. Some are relying more on discovery partnerships with local drug research entities in Japan. PharmAsia News' Tokyo bureau examines the factors behind the trend in this third article in a three-part series on the subject. Part one appeared in PharmAsia News on July 13, 2009, and part two appeared on July 20.

You may also be interested in...



Kobe Biocluster Looks To Support Partners, Novel Tech

The Foundation for Biomedical Research and Innovation (FBRI) co-ordinates Kobe’s life sciences activities and heads up the Biomedical Kansai network, Japan’s largest biocluster. It is seeking international life sciences investors and partners for licensing, co-development and funding options.

Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets

WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay

Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets

WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay

Related Content

UsernamePublicRestriction

Register

SC072302

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel